Sang Cheul Oh

University of Oregon — United States

Medicine · Health Sciences

47h-index13.3kcitations383works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(98), Cholangiocarcinoma and Gallbladder Cancer Studies(52), Colorectal Cancer Treatments and Studies(49), Hedgehog Signaling Pathway Studies(40), Lung Cancer Treatments and Mutations(34)

Publications381 total

Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
Clinical Cancer Research·2025Open Access
Trans cinnamaldehyde enhances TRAIL induced apoptosis through ER stress mediated upregulation of DR5 in colorectal cancer cells
Scientific Reports·2025Open Access
Dimethylindanoylindole isomers revealed different pharmacological profiles at CB1 and CB2 cannabinoid receptors
2025Open Access
LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study
Annals of Oncology·2025· 1 cited
Synergistic Anticancer Effects of Fibroblast Growth Factor Receptor Inhibitor and Cannabidiol in Colorectal Cancer
Nutrients·2025Open Access
Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis
2025Open Access
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Cancer Research and Treatment·2025· 2 citedOpen Access
Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor
Biomacromolecules·2025· 3 citedOpen Access
Abstract 518: Repurposing of pralatrexate in gastric cancer: Inducing cell death via SMO inhibition and GLI1 suppression
Cancer Research·2025
Abstract 5220: Regulating tumor-associated macrophage polarization via inhibition of hedgehog signaling for treating colorectal cancer liver metastasis
Cancer Research·2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
Journal of Hepatology·2025· 7 citedOpen Access
Superagonism in Synthetic Cannabinoid Receptor Agonists containing l-Tert-Leucinate (Abstract ID: 158755)
Journal of Pharmacology and Experimental Therapeutics·2025
OP02-5 Three-year survival and safety analysis from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer with Korean subset
ESMO Open·2025Open Access
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
Journal of Clinical Oncology·2025
Applying computational protein design to engineer affibodies for affinity-controlled delivery of vascular endothelial growth factor and platelet-derived growth factor
2024· 1 citedOpen Access
Supplementary Figure 2 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
2024Open Access
Supplementary Table 4 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
2024Open Access
Supplementary Figure 5 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
2024Open Access
Supplementary Table 1 from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
2024Open Access
Data from Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
2024Open Access
page 1 of 20Next →

Frequent Co-authors

Yoon‐Koo Kang(16), Keun‐Wook Lee(11), Min‐Hee Ryu(10), Hyun Cheol Chung(10), Jung Lim Kim(10), Narikazu Boku(9), Dae-Hee Lee(9), Kei Muro(8), Yoon A Jeong(8), Seong Hye Park(8), Yoo Jin Na(8), Yee Chao(7), Won Ki Kang(7), Jong Gwang Kim(7), Y. Choi(7), Soyeon Jeong(7), Min Jee Jo(7), Ken Kato(6), Jen‐Shi Chen(6), Do‐Youn Oh(6)